三酰甘油水平對冠狀動脈粥樣硬化性心臟病影響的研究進展_West China Medical Journal

Authors：

劉瑞雙 ¹ , 黃方洋 ² ,  陳茂 ²

1. ;
2. ;

Corresponding?author：

陳茂, Email: hmaochen@vip.sina.com

Keywords：

冠狀動脈粥樣硬化性心臟病; 三酰甘油; 預后

DOI：

10.7507/1002-0179.201608141

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

冠狀動脈粥樣硬化性心臟病（冠心病）發病率高，預后差，是全球范圍內導致死亡的主要原因之一。眾所周知，高脂血癥是冠心病的主要危險因素，目前多數研究主要聚焦于膽固醇和低密度脂蛋白水平對冠心病發病及預后的影響，而對于血脂中另一種成分—三酰甘油，對冠心病的影響研究相對較少。以往研究發現高三酰甘油血癥患者冠心病發病率增加且預后不良；近期則研究報道了非空腹三酰甘油也與冠心病的發病及預后相關，同時發現高三酰甘油血癥的影響在一些特殊人群（青年、女性）中尤為顯著。基于最近對高三酰甘油血癥在冠心病中的新認識，該文就三酰甘油水平對冠心病影響的研究進展進行了綜述。

Citation： 劉瑞雙, 黃方洋, 陳茂. 三酰甘油水平對冠狀動脈粥樣硬化性心臟病影響的研究進展. West China Medical Journal, 2017, 32(5): 763-767. doi: 10.7507/1002-0179.201608141 Copy

1.	?Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095-2128.
2.	陳偉偉, 高潤霖, 劉力生, 等. 《中國心血管病報告 2014》概要. 中國循環雜志, 2015(7): 617-622.
3.	胡大一, 郭藝芳. 甘油三酯增高的血脂異常防治中國專家共識. 中國醫學前沿雜志:電子版, 2011(05): 115-120.
4.	中國成人血脂異常防治指南指導聯合委員會. 中國成人血脂異常防治指南. 中華心血管病雜志, 2007, 35(5): 390-419.
5.	王彬堯, 王長謙. 甘油三酯與冠心病的關系. 國外醫學. 心血管疾病分冊, 2000(2): 79-81.
6.	李建薇, 田浩明. 餐后甘油三酯代謝障礙與冠心病. 國外醫學: 內科學分冊, 2001, 28(11): 461-463, 479.
7.	Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem, 2008, 317(1/2): 197-204.
8.	Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation, 2008, 118(7): 731-742.
9.	Canou?-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc Dis, 2010, 30(3): 252-259.
10.	Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J, 1986, 112(2): 432-437.
11.	Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol, 1996, 77(14): 1179-1184.
12.	Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease Independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk, 1996, 3(2): 213-219.
13.	Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004, 110(17): 2678-2686.
14.	Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis, 2010, 210(1): 243-248.
15.	Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation, 1998, 97(11): 1029-1036.
16.	Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb, 1991, 11(1): 2-14.
17.	Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009, 302(18): 1993-2000.
18.	Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011, 123(20): 2292-2333.
19.	Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366(9493): 1267-1278.
20.	Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol, 2009, 104(4): 459-463.
21.	Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol, 2001, 87(5A): 2B-7B.
22.	He Y, Lam TH, Li LS, et al. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol, 2004, 14(1): 1-7.
23.	Werner C, Filmer A, Fritsch M, et al. Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. Clin Res Cardiol, 2014, 103(12): 984-997.
24.	Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the baltimore coronary observational long-term study. J Am Coll Cardiol, 1998, 31(6): 1252-1257.
25.	von Eynatten M, Hamann A, Twardella D, et al. Atherogenic dyslipidaemia but not total-and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J, 2008, 29(10): 1307-1315.
26.	Yun KH, Shin IS, Rhee SJ, et al. Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med, 2009, 24(4): 330-336.
27.	Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk, 2000, 7(5): 339-345.
28.	Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol, 1993, 71(11): 909-915.
29.	Goldbourt U, Brunner D, Behar S, et al. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J, 1998, 19(Suppl H): H42-H47.
30.	Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999, 341(6): 410-418.
31.	Lisak M, Demarin V, Trkanjec Z, et al. Hypertriglyceridemia as a possible independent risk factor for stroke. Acta Clin Croat, 2013, 52(4): 458-463.
32.	Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol, 2000, 86(12A): 23L-27L.
33.	Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 2008, 51(7): 724-730.
34.	趙水平. 《甘油三酯增高的血脂異常防治中國專家共識》解讀. 內科理論與實踐, 2011, 6(6): 408-411.
35.	Driver SL, Martin SS, Gluckman TJ, et al. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol, 2016, 67(10): 1227-1234.
36.	Patsch JR, Miesenb?ck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb, 1992, 12(11): 1336-1345.
37.	Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ, 1996, 312(736): 935-939.
38.	Braun D, Gramlich A, Brehme U, et al. Post-prandial lipaemia after a moderate fat challenge in normolipidaemic men with and without coronary artery disease. J Cardiovasc Risk, 1997, 4(2): 143-149.
39.	Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007, 298(3): 299-308.
40.	Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008, 300(18): 2142-2152.
41.	Rajkumar C, Simpson H, Jennings GL, et al. Postprandial silent ischaemia following a fatty meal in patients with recently diagnosed coronary artery disease. J Hum Hypertens, 2000, 14(6): 391-394.
42.	Pineda J, Marín F, Marco P, et al. Premature coronary artery disease in young (age<45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol, 2009, 136(2): 222-225.
43.	厲其昀. 高甘油三酯血癥與早發冠心病的關系. 現代醫藥衛生, 2006, 22(7): 974-975.
44.	楊金玲, 李廣平. 青年急性心肌梗死臨床特點與冠狀動脈造影分析. 臨床薈萃, 2014(9): 961-964.
45.	Sabik JF, Blackstone EH, Gillinov AM, et al. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation, 2006, 114(1 Suppl): I454-I460.
46.	Kasai T, Miyauchi K, Yanagisawa N, et al. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart, 2013, 99(1): 22-29.
47.	Rami Helvaci M, Kaya H, Gundogdu M. Gender differences in patients with metabolic syndrome in coronary artery interventions. Med Glas (Zenica), 2013, 10(1): 75-80.
48.	Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988, 4(Suppl A): 5A-10A.

1. ?Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095-2128.
2. 陳偉偉, 高潤霖, 劉力生, 等. 《中國心血管病報告 2014》概要. 中國循環雜志, 2015(7): 617-622.
3. 胡大一, 郭藝芳. 甘油三酯增高的血脂異常防治中國專家共識. 中國醫學前沿雜志:電子版, 2011(05): 115-120.
4. 中國成人血脂異常防治指南指導聯合委員會. 中國成人血脂異常防治指南. 中華心血管病雜志, 2007, 35(5): 390-419.
5. 王彬堯, 王長謙. 甘油三酯與冠心病的關系. 國外醫學. 心血管疾病分冊, 2000(2): 79-81.
6. 李建薇, 田浩明. 餐后甘油三酯代謝障礙與冠心病. 國外醫學: 內科學分冊, 2001, 28(11): 461-463, 479.
7. Zhao R, Ma X, Shen GX. Transcriptional regulation of plasminogen activator inhibitor-1 in vascular endothelial cells induced by oxidized very low density lipoproteins. Mol Cell Biochem, 2008, 317(1/2): 197-204.
8. Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation, 2008, 118(7): 731-742.
9. Canou?-Poitrine F, Luc G, Bard JM, et al. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study. Cerebrovasc Dis, 2010, 30(3): 252-259.
10. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J, 1986, 112(2): 432-437.
11. Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol, 1996, 77(14): 1179-1184.
12. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease Independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk, 1996, 3(2): 213-219.
13. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation, 2004, 110(17): 2678-2686.
14. Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis, 2010, 210(1): 243-248.
15. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation, 1998, 97(11): 1029-1036.
16. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb, 1991, 11(1): 2-14.
17. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009, 302(18): 1993-2000.
18. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011, 123(20): 2292-2333.
19. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366(9493): 1267-1278.
20. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol, 2009, 104(4): 459-463.
21. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol, 2001, 87(5A): 2B-7B.
22. He Y, Lam TH, Li LS, et al. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol, 2004, 14(1): 1-7.
23. Werner C, Filmer A, Fritsch M, et al. Risk prediction with triglycerides in patients with stable coronary disease on statin treatment. Clin Res Cardiol, 2014, 103(12): 984-997.
24. Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: the baltimore coronary observational long-term study. J Am Coll Cardiol, 1998, 31(6): 1252-1257.
25. von Eynatten M, Hamann A, Twardella D, et al. Atherogenic dyslipidaemia but not total-and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J, 2008, 29(10): 1307-1315.
26. Yun KH, Shin IS, Rhee SJ, et al. Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Korean J Intern Med, 2009, 24(4): 330-336.
27. Rubins HB. Triglycerides and coronary heart disease: implications of recent clinical trials. J Cardiovasc Risk, 2000, 7(5): 339-345.
28. Goldbourt U, Behar S, Reicher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol, 1993, 71(11): 909-915.
29. Goldbourt U, Brunner D, Behar S, et al. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J, 1998, 19(Suppl H): H42-H47.
30. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 1999, 341(6): 410-418.
31. Lisak M, Demarin V, Trkanjec Z, et al. Hypertriglyceridemia as a possible independent risk factor for stroke. Acta Clin Croat, 2013, 52(4): 458-463.
32. Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol, 2000, 86(12A): 23L-27L.
33. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 2008, 51(7): 724-730.
34. 趙水平. 《甘油三酯增高的血脂異常防治中國專家共識》解讀. 內科理論與實踐, 2011, 6(6): 408-411.
35. Driver SL, Martin SS, Gluckman TJ, et al. Fasting or nonfasting lipid measurements: it depends on the question. J Am Coll Cardiol, 2016, 67(10): 1227-1234.
36. Patsch JR, Miesenb?ck G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb, 1992, 12(11): 1336-1345.
37. Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ, 1996, 312(736): 935-939.
38. Braun D, Gramlich A, Brehme U, et al. Post-prandial lipaemia after a moderate fat challenge in normolipidaemic men with and without coronary artery disease. J Cardiovasc Risk, 1997, 4(2): 143-149.
39. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007, 298(3): 299-308.
40. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008, 300(18): 2142-2152.
41. Rajkumar C, Simpson H, Jennings GL, et al. Postprandial silent ischaemia following a fatty meal in patients with recently diagnosed coronary artery disease. J Hum Hypertens, 2000, 14(6): 391-394.
42. Pineda J, Marín F, Marco P, et al. Premature coronary artery disease in young (age<45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol, 2009, 136(2): 222-225.
43. 厲其昀. 高甘油三酯血癥與早發冠心病的關系. 現代醫藥衛生, 2006, 22(7): 974-975.
44. 楊金玲, 李廣平. 青年急性心肌梗死臨床特點與冠狀動脈造影分析. 臨床薈萃, 2014(9): 961-964.
45. Sabik JF, Blackstone EH, Gillinov AM, et al. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation, 2006, 114(1 Suppl): I454-I460.
46. Kasai T, Miyauchi K, Yanagisawa N, et al. Mortality risk of triglyceride levels in patients with coronary artery disease. Heart, 2013, 99(1): 22-29.
47. Rami Helvaci M, Kaya H, Gundogdu M. Gender differences in patients with metabolic syndrome in coronary artery interventions. Med Glas (Zenica), 2013, 10(1): 75-80.
48. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol, 1988, 4(Suppl A): 5A-10A.

Previous Article
Analysis on prescription dispensing error and its avoidance in outpatient pharmacy
Next Article
CD36 與慢性腎臟病

West China Medical Journal

三酰甘油水平對冠狀動脈粥樣硬化性心臟病影響的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content